Pluristyx, a leader in induced pluripotent stem cell (iPSC) technologies and gene editing, has completed its latest funding round, led by BioLife Solutions and BroadOak Capital Partners.
The new capital will enable Pluristyx to expand its inventory of clinical-grade iPSC lines, incorporating proprietary FailSafe and iACT engineering, along with hypoimmune genetic edits. These advanced cells aim to support next-generation, genetically engineered therapies that are safe, effective, and scalable.
Additionally, the funding will help grow and commercialize the PluriForm kit, which streamlines the generation of organoids and complex test systems for researchers.
iPSCs are essential for developing new medicines and can replace animal models in toxicology, safety, and efficacy assays. This investment strengthens Pluristyx’s position as a leader in high-quality stem cell provision.
KEY QUOTES:
“We are incredibly excited for the successful close of this round and gratified to have industry leaders and peers validate our vision with their investment. The support from our Seattle area neighbor, BioLife Solutions, and continued support from our colleagues at BroadOak Partners will allow us to manufacture, commercialize, and distribute our innovative solutions and help our customers solve critical industry challenges.”
Benjamin Fryer, PhD, CEO of Pluristyx
“We have known and worked with the founding team at Pluristyx for many years, and have a great deal of respect for their scientific expertise in cell therapy. Their recent development of an iPSC-based biological assay for organoid manufacturing dovetails with our interest in exploring biological assays more broadly as a product portfolio adjacency.”
Roderick de Greef, BioLife’s Chairman and CEO
“We are excited to continue our support of Dr. Fryer and the entire Pluristyx team. Pluristyx is differentiated by its suite of proprietary technologies that directly address some of the most critical scientific challenges of the iPSC field.”
Daniel Friedman, Principal at BroadOak Capital Partners
